|
1
|
Siegel R, Naishadham D and Jemal A: Cancer
statistics, 2013. CA Cancer J Clin. 63:11–30. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Weidle UH, Birzele F, Kollmorgen G and
Rueger R: Mechanisms and targets involved in dissemination of
ovarian cancer. Cancer Genomics Proteomics. 13:407–423. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Lavoué V, Thédrez A, Levêque J, Foucher F,
Henno S, Jauffret V, Belaud-Rotureau MA, Catros V and Cabillic F:
Immunity of human epithelial ovarian carcinoma: The paradigm of
immune suppression in cancer. J Transl Med. 11:1472013. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Mei L, Chen H, Wei DM, Fang F, Liu GJ, Xie
HY, Wang X, Zou J, Han X and Feng D: Maintenance chemotherapy for
ovarian cancer. Cochrane Database Syst Rev CD007414. 2013.
View Article : Google Scholar
|
|
5
|
Tan DS and Kaye S: Ovarian clear cell
adenocarcinoma: A continuing enigma. J Clin Pathol. 60:355–360.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Barbolina MV, Kim M, Liu Y, Shepard J,
Belmadani A, Miller RJ, Shea LD and Stack MS: Microenvironmental
regulation of chemokine (C-X-C-motif) receptor 4 in ovarian
carcinoma. Mol Cancer Res. 8:653–664. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Zlotnik A: Chemokines and cancer. Int J
Cancer. 119:2026–2029. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Balakin KV, Ivanenkov YA, Tkachenko SE,
Kiselyov AS and Ivachtchenko AV: Regulators of chemokine receptor
activity as promising anticancer therapeutics. Curr Cancer Drug
Targets. 8:299–340. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Soria G, Yaal-Hahoshen N, Azenshtein E,
Shina S, Leider-Trejo L, Ryvo L, Cohen-Hillel E, Shtabsky A,
Ehrlich M, Meshel T, et al: Concomitant expression of the
chemokines RANTES and MCP-1 in human breast cancer: A basis for
tumor-promoting interactions. Cytokine. 44:191–200. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Soria G and Ben-Baruch A: The inflammatory
chemokines CCL2 and CCL5 in breast cancer. Cancer Lett.
267:271–285. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Feng LY, Ou ZL, Wu FY, Shen ZZ and Shao
ZM: Involvement of a novel chemokine decoy receptor CCX-CKR in
breast cancer growth, metastasis and patient survival. Clin Cancer
Res. 15:2962–2970. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Wu FY, Ou ZL, Feng LY, Luo JM, Wang LP,
Shen ZZ and Shao ZM: Chemokine decoy receptor d6 plays a negative
role in human breast cancer. Mol Cancer Res. 6:1276–1288. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Wang J, Ou ZL, Hou YF, Luo JM, Shen ZZ,
Ding J and Shao ZM: Enhanced expression of Duffy antigen receptor
for chemokines by breast cancer cells attenuates growth and
metastasis potential. Oncogene. 25:7201–7211. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Zhang L, Yang N, Park JW, Katsaros D,
Fracchioli S, Cao G, O'Brien-Jenkins A, Randall TC, Rubin SC and
Coukos G: Tumor-derived vascular endothelial growth factor
up-regulates angiopoietin-2 in host endothelium and destabilizes
host vasculature, supporting angiogenesis in ovarian cancer. Cancer
Res. 63:3403–3412. 2003.PubMed/NCBI
|
|
15
|
Folkman J: Tumor angiogenesis: Therapeutic
implications. N Engl J Med. 285:1182–1186. 1971. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Rot A: Contribution of Duffy antigen to
chemokine function. Cytokine Growth Factor Rev. 16:687–694. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Balkwill F: Cancer and the chemokine
network. Nat Rev Cancer. 4:540–550. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Zhao HB, Tang CL, Hou YL, Xue LR, Li MQ,
Du MR and Li DJ: CXCL12/CXCR4 axis triggers the activation of EGF
receptor and ERK signaling pathway in CsA-induced proliferation of
human trophoblast cells. PLoS One. 7:e383752012. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Szabo MC, Soo KS, Zlotnik A and Schall TJ:
Chemokine class differences in binding to the Duffy
antigen-erythrocyte chemokine receptor. J Biol Chem.
270:25348–25351. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Latini FR, Bastos AU, Arnoni CP, Muniz JG,
Person RM, Baleotti W Jr, Barreto JA, Castilho L and Cerutti JM:
DARC (Duffy) and BCAM (Lutheran) reduced expression in thyroid
cancer. Blood Cells Mol Dis. 50:161–165. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Horne K and Woolley IJ: Shedding light on
DARC: The role of the Duffy antigen/receptor for chemokines in
inflammation, infection and malignancy. Inflamm Res. 58:431–435.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Neote K, Mak JY, Kolakowski LF Jr and
Schall TJ: Functional and biochemical analysis of the cloned Duffy
antigen: Identity with the red blood cell chemokine receptor.
Blood. 84:44–52. 1994.PubMed/NCBI
|
|
23
|
Graham GJ, Locati M, Mantovani A, Rot A
and Thelen M: The biochemistry and biology of the atypical
chemokine receptors. Immunol Lett. 145:30–38. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Ulvmar MH, Hub E and Rot A: Atypical
chemokine receptors. Exp Cell Res. 317:556–568. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Wang D, Dubois RN and Richmond A: The role
of chemokines in intestinal inflammation and cancer. Curr Opin
Pharmacol. 9:688–696. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Addison CL, Belperio JA, Burdick MD and
Strieter RM: Overexpression of the duffy antigen receptor for
chemokines (DARC) by NSCLC tumor cells results in increased tumor
necrosis. BMC Cancer. 4:282004. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Lentsch AB: The Duffy antigen/receptor for
chemokines (DARC) and prostate cancer. A role as clear as black and
white? FASEB J. 16:1093–1095. 2002.
|
|
28
|
McClellan JL, Davis JM, Steiner JL, Enos
RT, Jung SH, Carson JA, Pena MM, Carnevale KA, Berger FG and Murphy
EA: Linking tumor-associated macrophages, inflammation, and
intestinal tumorigenesis: Role of MCP-1. Am J Physiol Gastrointest
Liver Physiol. 303:G1087–G1095. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Doll D, Keller L, Maak M, Boulesteix AL,
Siewert JR, Holzmann B and Janssen KP: Differential expression of
the chemokines GRO-2, GRO-3, and interleukin-8 in colon cancer and
their impact on metastatic disease and survival. Int J Colorectal
Dis. 25:573–581. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Ning Y, Manegold PC, Hong YK, Zhang W,
Pohl A, Lurje G, Winder T, Yang D, LaBonte MJ, Wilson PM, et al:
Interleukin-8 is associated with proliferation, migration,
angiogenesis and chemosensitivity in vitro and in vivo in colon
cancer cell line models. Int J Cancer. 128:2038–2049. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Wang J, Ou ZL, Hou YF, Luo JM, Chen Y,
Zhou J, Shen ZZ, Ding J and Shao ZM: Duffy antigen receptor for
chemokines attenuates breast cancer growth and metastasis: An
experiment with nude mice. Zhonghua Yi Xue Za Zhi. 85:2033–2037.
2005.PubMed/NCBI
|
|
32
|
Zeng XH, Ou ZL, Yu KD, Feng LY, Yin WJ, Li
J, Shen ZZ and Shao ZM: Coexpression of atypical chemokine binders
(ACBs) in breast cancer predicts better outcomes. Breast Cancer Res
Treat. 125:715–727. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Sun G, Wang Y, Zhu Y, Huang C and Ji Q:
Duffy antigen receptor for chemokines in laryngeal squamous cell
carcinoma as a negative regulator. Acta Otolaryngol. 131:197–203.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Bandyopadhyay S, Zhan R, Chaudhuri A,
Watabe M, Pai SK, Hirota S, Hosobe S, Tsukada T, Miura K, Takano Y,
et al: Interaction of KAI1 on tumor cells with DARC on vascular
endothelium leads to metastasis suppression. Nat Med. 12:933–938.
2006. View
Article : Google Scholar : PubMed/NCBI
|
